The 65 rating InvestorsObserver gives to Crispr Therapeutics AG (CRSP) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 80 percent of stocks in the Biotechnology industry, CRSP’s 65 overall rating means the stock scores better than 65 percent of all stocks.
What do These Ratings Mean?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is down -4.15% while the S&P 500 is higher by 0.12% as of 10:57 AM on Tuesday, Dec 29. CRSP is down -$7.01 from the previous closing price of $168.93 on volume of 2,016,389 shares. Over the past year the S&P 500 has risen 16.09% while CRSP is higher by 161.84%. CRSP lost -$3.25 per share the over the last 12 months.